WATERTOWN, Mass. – March 26, 2018 – Macrolide Pharmaceuticals today announced it has been granted a CARB-X award of up to $6.8M to support the development of a novel fully synthetic, orally available macrolide antibiotic with Gram-negative activity, with the aim of treating serious infections including drug-resistant complicated urinary tract infections (cUTI).

“We are delighted to be partnering with CARB-X on this program to develop novel macrolides with first-in-class activity against drug-resistant Gram-negative pathogens,” said Richard Alm, Ph.D., Vice President of Biology and the collaboration’s Principal Investigator. “Rapidly increasing resistance in these organisms have reduced the effectiveness of many current antibiotic classes and created significant unmet clinical need. This award from CARB-X supports our efforts to leverage our powerful synthetic chemistry platform to develop novel therapeutics for patients with complicated urinary tract infections and will rapidly advance our lead candidates towards clinical trials.”

As an antibiotic class, macrolides are known to be effective against many Gram-positive pathogens, however, to date scientists have been unable to achieve macrolide activity against drug-resistant Gram-negative pathogens. Macrolide is leveraging its proprietary chemistry platform to re-engineer the macrolide scaffold with the aim of developing a new fully-synthetic macrolide antibiotic to treat drug-resistant Gram-negative infections that can be administered intravenously and orally. The company’s novel macrolides will also avoid macrolide-resistance mechanisms. The CARB-X funding will accelerate the company’s development program to reach human clinical studies.

 

Contacts

Macrolide Pharmaceuticals Company Contact
Mahesh Karande
mkarande@macrolide.com
or
Macrolide Pharmaceuticals Media Contact
Ten Bridge Communications
Krystle Gibbs, 508-479-6358
krystle@tenbridgecommunications.com